Caxton Associates LP purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,400 shares of the medical instruments supplier’s stock, valued at approximately $624,000.
Several other hedge funds have also bought and sold shares of the stock. Beese Fulmer Investment Management Inc. raised its stake in Becton, Dickinson and by 2.7% in the first quarter. Beese Fulmer Investment Management Inc. now owns 26,022 shares of the medical instruments supplier’s stock worth $4,773,000 after buying an additional 688 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in Becton, Dickinson and by 188.1% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 26,494 shares of the medical instruments supplier’s stock worth $4,881,000 after buying an additional 17,298 shares in the last quarter. Carderock Capital Management Inc. boosted its position in Becton, Dickinson and by 0.5% in the first quarter. Carderock Capital Management Inc. now owns 13,499 shares of the medical instruments supplier’s stock worth $2,476,000 after buying an additional 69 shares in the last quarter. Pinnacle Bank bought a new position in Becton, Dickinson and during the first quarter worth approximately $192,000. Finally, Doyle Wealth Management bought a new position in Becton, Dickinson and during the first quarter worth approximately $434,000. 75.71% of the stock is currently owned by institutional investors.
Becton, Dickinson and Company (BDX) traded up 1.08% during midday trading on Friday, hitting $200.36. 1,251,199 shares of the stock traded hands. The firm has a market cap of $45.59 billion, a PE ratio of 58.02 and a beta of 1.05. The company’s 50 day moving average price is $198.90 and its 200 day moving average price is $187.70. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63.
Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. During the same quarter last year, the firm posted $2.35 EPS. The business’s revenue was down 5.1% on a year-over-year basis. Equities research analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be given a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.46%. Becton, Dickinson and’s dividend payout ratio (DPR) is 83.43%.
COPYRIGHT VIOLATION WARNING: “Caxton Associates LP Invests $624,000 in Becton, Dickinson and Company (NYSE:BDX)” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://stocknewstimes.com/2017/08/12/caxton-associates-lp-invests-624000-in-becton-dickinson-and-company-nysebdx.html.
A number of brokerages have recently issued reports on BDX. Evercore ISI raised shares of Becton, Dickinson and from an “in-line” rating to an “outperform” rating and upped their price objective for the company from $186.00 to $200.00 in a research note on Monday, April 24th. Zacks Investment Research cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their price target for the company from $210.00 to $180.00 in a research report on Friday, June 30th. Cowen and Company restated an “outperform” rating and issued a $230.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. Finally, BidaskClub upgraded shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $195.79.
In other news, VP Jeffrey S. Sherman sold 28,765 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now owns 70,821 shares in the company, valued at approximately $13,171,289.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the transaction, the insider now directly owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The disclosure for this sale can be found here. Insiders have sold a total of 44,019 shares of company stock worth $8,368,433 in the last quarter. Insiders own 1.40% of the company’s stock.
About Becton, Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.